At the Hohhot Conference on Deepening the Integration of Technological Innovation and Industrial Innovation, held on August 25, the President of Jinyu Bio-Technology Co., Ltd., Zhang Jing, outlined the company's strategic vision for fusing artificial intelligence with biotechnology across its operations. She emphasized that during the "15th Five-Year Plan" period, the firm will aggressively promote the deep integration and innovation of AI and biotech within real-world application scenarios.
The core of this initiative centers on intelligent rapid detection and smart veterinary services, creating expansive use cases in animal disease prevention, zoonotic disease control, pet health management, and research on emerging infectious diseases. These efforts aim to unlock value across the livestock and biomedical industries, enhancing efficiency and boosting the brand value of food products through improved supply chains.
On the research and development front, Jinyu Bio-Technology is deepening AI-assisted antigen screening and structural optimization to accelerate vaccine iteration cycles. In production, the company is reinforcing its smart manufacturing systems to ensure high-quality delivery, while also leveraging AI to improve the efficiency of marketing, finance, and human resources departments. This holistic approach is designed to elevate the company's overall management capabilities.
A key priority is the expedited review and registration of the African swine fever subunit vaccine, a breakthrough expected to generate ten billion yuan in output value. Beyond internal applications, the company is innovating with AI and biotech in external scenarios to bolster the high-quality development of the livestock industry. Through intelligent rapid detection and smart veterinary services, Jinyu Bio-Technology is building a closed-loop system that integrates epidemic data collection, computational algorithms, veterinary model training, and precise prevention and control measures.
Zhang Jing highlighted that the company has established five agile teams this year, staffed by professionals proficient in both veterinary science and AI. These teams work directly at livestock farms to conduct on-site testing, implement precise solutions, and promote successful case studies. This marks a strategic shift from traditional vaccine manufacturing to a new model of innovation that combines scientific research, smart detection, veterinary expertise, vaccine development, immune purification, quality enhancement, food safety, and brand value creation.
Underpinning these efforts is a commitment to sustained investment, with an annual R&D budget of 200 million yuan and a total of no less than 1 billion yuan over the next five years. The company will leverage its four national and provincial-level innovation platforms, focusing on core technology breakthroughs, pilot-scale validation, and industrialization. A particular emphasis is placed on next-generation vaccines, such as mRNA-based products, to build a platform for independent intellectual property and industrialization.
Zhang Jing further noted that the company is closely following the autonomous region's "AI Plus" action plan, accelerating the development of AI-assisted vaccine R&D, intelligent detection reagents and devices, and smart veterinary diagnostic platforms. In parallel, the firm is investing in both research and talent development, utilizing its academician expert workstation and deepening its "flyover laboratory" model. This strategy aims to cultivate a new generation of young professionals who understand biotechnology, AI, and practical applications, fostering an ecosystem where "introducing one academician brings in a team, trains a cohort of key personnel, and drives an entire industry."